- Home
- ZWS vs BLCO Comparison
ZWS vs BLCO Comparison
Compare ZWS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZWS
- BLCO
- Stock Information
- Founded
- ZWS 1892
- BLCO 1853
- Country
- ZWS United States
- BLCO Canada
- Employees
- ZWS N/A
- BLCO N/A
- Industry
- ZWS Industrial Machinery/Components
- BLCO Ophthalmic Goods
- Sector
- ZWS Industrials
- BLCO Health Care
- Exchange
- ZWS Nasdaq
- BLCO Nasdaq
- Market Cap
- ZWS 6.1B
- BLCO 6.3B
- IPO Year
- ZWS 2012
- BLCO 2022
- Fundamental
- Price
- ZWS $38.84
- BLCO $17.17
- Analyst Decision
- ZWS Buy
- BLCO Buy
- Analyst Count
- ZWS 6
- BLCO 12
- Target Price
- ZWS $38.50
- BLCO $20.73
- AVG Volume (30 Days)
- ZWS 940.4K
- BLCO 396.1K
- Earning Date
- ZWS 02-04-2025
- BLCO 02-19-2025
- Dividend Yield
- ZWS 0.93%
- BLCO N/A
- EPS Growth
- ZWS 24.05
- BLCO N/A
- EPS
- ZWS 0.79
- BLCO N/A
- Revenue
- ZWS $1,552,600,000.00
- BLCO $4,684,000,000.00
- Revenue This Year
- ZWS $3.10
- BLCO $17.32
- Revenue Next Year
- ZWS $3.74
- BLCO $5.98
- P/E Ratio
- ZWS $49.45
- BLCO N/A
- Revenue Growth
- ZWS 2.55
- BLCO 18.01
- 52 Week Low
- ZWS $28.25
- BLCO $13.16
- 52 Week High
- ZWS $41.15
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- ZWS 59.20
- BLCO 35.11
- Support Level
- ZWS $35.75
- BLCO $17.00
- Resistance Level
- ZWS $37.63
- BLCO $17.57
- Average True Range (ATR)
- ZWS 0.78
- BLCO 0.45
- MACD
- ZWS 0.23
- BLCO -0.00
- Stochastic Oscillator
- ZWS 92.24
- BLCO 22.80
About ZWS Zurn Elkay Water Solutions Corporation
Zurn Elkay Water Solutions Corp designs procure, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The Zurn Elkay product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.